Clinical Trial Update: Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail [Phase 4]

View source ↗

Summary

A phase 4 randomized trial evaluating whether celecoxib prevents hand-foot syndrome caused by sorafenib in hepatocellular carcinoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Celecoxib (Celecoxib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma | Phase 4 | Status: COMPLETED